Olaparib Maintenance Therapy Delays Ovarian Cancer Progression - NCI
PARP Inhibitors in Ovarian Cancer | IntechOpen
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors - ScienceDirect
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review - Gynecologic Oncology
Cancer Research Highlight: PARP Inhibition Sets A New Benchmark For Ovarian Cancer (NASDAQ:AZN) | Seeking Alpha
Rucaparib Approved as Maintenance Therapy for Ovarian Cancer - NCI
PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer - ScienceDirect
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair | American Society of Clinical Oncology Educational Book
Update on PARP1 inhibitors in ovarian cancer - Annals of Oncology
PARPi Pharmacist Considerations - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations - Gynecologic Oncology
American Society of Clinical Oncology - Now available: New guideline on PARP inhibitors in the management of ovarian cancer https://fal.cn/39IVS | Facebook
An Ovarian Cancer Roundtable: The Role of PARP Inhibitors in the Treatment of Ovarian Cancer
Enrolling Clinical Trials: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer - Penn Medicine
Clinical trials results for PARP Inhibitors in ovarian cancer. | Download Table
FDA-EMA approved indications for PARP inhibitors in ovarian cancer. | Download Table
PARP inhibitors: Choosing what to use in epithelial ovarian cancer
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance | Bentham Science
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway - ScienceDirect
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
